Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2024 Feb 20;18(2):e0011964. doi: 10.1371/journal.pntd.0011964

Prevalence and changing antimicrobial resistance profiles of Shigella spp. isolated from diarrheal patients in Kolkata during 2011–2019

Puja Bose 1, Goutam Chowdhury 1,2, Gourab Halder 1, Debjani Ghosh 1, Alok K Deb 3, Kei Kitahara 2,4, Shin-ichi Miyoshi 2,4, Masatomo Morita 5, Thandavarayan Ramamurthy 1, Shanta Dutta 1, Asish Kumar Mukhopadhyay 1,*
Editor: Sivanantham Krishnamoorthi6
PMCID: PMC10906866  PMID: 38377151

Abstract

Background

The primary aim of this study was to investigate the occurrence, characteristics, and antimicrobial resistance patterns of various Shigella serogroups isolated from patients with acute diarrhea of the Infectious Diseases Hospital in Kolkata from 2011–2019.

Principal findings

During the study period, Shigella isolates were tested for their serogroups, antibiotic resistance pattern and virulence gene profiles. A total of 5.8% of Shigella spp. were isolated, among which S. flexneri (76.1%) was the highest, followed by S. sonnei (18.7%), S. boydii (3.4%), and S. dysenteriae (1.8%). Antimicrobial resistance against nalidixic acid was higher in almost all the Shigella isolates, while the resistance to β-lactamases, fluoroquinolones, tetracycline, and chloramphenicol diverged. The occurrence of multidrug resistance was found to be linked with various genes encoding drug-resistance, multiple mutations in the topoisomerase genes, and mobile genetic elements. All the isolates were positive for the invasion plasmid antigen H gene (ipaH). Dendrogram analysis of the plasmid and pulsed-field electrophoresis (PFGE) profiles revealed 70–80% clonal similarity among each Shigella serotype.

Conclusion

This comprehensive long-term surveillance report highlights the clonal diversity of clinical Shigella strains circulating in Kolkata, India, and shows alarming resistance trends towards recommended antibiotics. The elucidation of this study’s outcome is helpful not only in identifying emerging antimicrobial resistance patterns of Shigella spp. but also in developing treatment guidelines appropriate for this region.

Author summary

Shigella spp. is one of the WHO-designated "antibiotic-resistant priority pathogens" that is the leading cause of bacterial diarrhea among children worldwide. The distribution of Shigella species varies depending on the geographic location, particularly in regions where environmental risk factors like substandard water quality, limited healthcare accessibility, and insufficient sanitation are widespread. The presence of serotype diversity and drug resistance combinations often leads to treatment failures. Therefore, it is crucial to comprehend the prevailing serogroups and antimicrobial resistance patterns of Shigella species in different geographical areas to implement effective treatment strategies. We have identified 535 Shigella positive cases from 9276 diarrheal cases. Multidrug-resistant (MDR) Shigella globally requires a profound understanding of its genetic diversity, as there is significant regional variation in MDR strains. In our study, we observed a broad spectrum of resistance among the Shigella strains, with over 53.6% of the isolates demonstrating multidrug resistance. Representative isolates were evaluated for antimicrobial resistance encoding and virulence-associated genes as they enact significantly in disease development and interaction with the host immune system. This report marks the initial presentation of the outcomes from long-term surveillance and molecular characterization of antimicrobial resistances in clinical Shigella strains in Kolkata since 2011. The outcome of this investigations will guide in identifying emerging antimicrobial resistance trend, formulating suitable treatment guidelines tailored to the community’s needs, and establishing baseline data for comparison with potential outbreak strains in the future.

Introduction

Shigella spp. is one of the listed "antibiotic-resistant priority pathogens" that pose a significant risk to global health (WHO, 2017) and are responsible for acute invasive intestinal infection leading to dysentery characterised by watery or bloody diarrhea [1,2]. Shigella spp. (S. dysenteriae, S. flexneri, S. boydii, and S. sonnei) is the etiological agent of shigellosis, and its species distribution varies spatio-temporally. The frequency of isolation of S. flexneri is more in developing and less developed countries, whereas S. sonnei has been reported as a major threat in developed regions [3]. Both endemic and epidemic shigellosis are caused by many serotypes of S. flexneri and S. dysenteriae type 1 [4].

Globally, 165 million shigellosis cases have been reported every year in low- to middle-income countries, with more than 1 million deaths per year [5]. Access to clean water, good nutrition, sustained sanitation, and healthcare play a key role in reducing the disease burden [6,7]. Shigella has also been found to be the leading causative agent of childhood diarrhea, affecting 1.1 million children per year, predominantly infants to an age group below 5 years old [8].

In addition to the characteristic of a low infective dose, a major role in the pathophysiology of the disease and its interaction with the host immune system was played by the virulence characteristics of Shigella [9]. Amidst numerous well-known virulence factors associated with Shigella spp, invasion plasmid antigen (Ipa) and the invasion-associated locus (Ial), facilitate intestinal cell penetration. The other factors, such as Shigella enterotoxin 1 (ShET-1) and Shigella enterotoxin 2 (ShET-2) are encoded by the chromosomally-located set gene, set1, and the plasmid-encoded gene sen, respectively [10]. Plasmid-derived VirF and VirB proteins control invasion-related gene transcription. Shigella spp. harbour toxic factors like serine protease autotransporters of Enterobacteriaceae (SPATE) that include class 1 toxins, Shigella IgA-like protease homologue (SigA), and secreted autotransporter toxin (Sat). The other is non-toxic SPATE class 2 toxins, which include the extracellular serine protease (sepA), whose association is mainly with intestinal inflammation, and colonisation [11]. Pulsed-field electrophoresis (PFGE) is the most popular technique used to distinguish clonal isolates among various molecular methods employed for strain typing [12].

Although Shigella seems to be a self-limiting disease, the WHO guidelines recommend antimicrobials in the treatment of the disease to control epithelial infiltration, duration of diarrhea, severity of symptoms, disease carrier stage, and death incidence [13]. The treatment of shigellosis has become more challenging due to the emergence of multidrug-resistant (MDR) strains. Consequently, MDR strains of Shigella are increasingly reported to be resistant to most of the recommended antimicrobials, like ciprofloxacin, third-generation cephalosporin, ceftriaxone, and macrolide azithromycin [8]. Current data suggests an annual global fatality rate of approximately 700,000 due to antimicrobial resistance (AMR) [5].

AMR is also reported to be associated with a variety of biological, pharmacological, and social variables, like this organism’s ability to acquire extra genetic material in the form of plasmids, pathogenicity islands, transposons, etc., as well as indiscriminate antibiotic use [1418]. Significant regional variation in MDR Shigella across the world makes it crucial to depend on information about its genetic diversity in determining epidemiological shifts as well as the development of appropriate treatment methods.

Different studies have been made across the world to track the epidemiology and antimicrobial susceptibility patterns of Shigella spp. [5,1922]. MDR Shigella spp. has shown a rising trend in Kolkata, particularly in relation to the fluoroquinolone class of antimicrobials [23]. However, there has been a dearth of information related to prevalence and the AMR pattern in Shigella strains isolated from Kolkata and its surrounding areas since 2010. Hence, the present study aimed to determine the epidemiological pattern of shigellosis and its antimicrobial resistance (AMR) patterns in this particular region.

Materials and methods

1. Ethics statement

Informed written consent was obtained from the eligible cases or their legal guardian after explaining to them the purpose of this study. The work carried out in this study was approved by the Institutional Ethical Committee (IEC) of ICMR-National Institute of Cholera and Enteric Diseases (NICED), Kolkata, India (approved no. A-1/2015-IEC).

2. Study design

From January 2011 through December 2019, 9276 enrolled patients with diarrhoea at Infectious Disease Hospital, Kolkata, were tested, and 535 (5.8%) were found to have Shigella spp. Stool samples were tested for common enteric pathogens using standard microbiological methods within 2 hours of collection [24]. Antisera from a commercial supplier (Denka Seiken Co. Ltd., Tokyo, Japan) were used in slide agglutination tests to verify the identification of Shigella spp. isolates based on biochemical methods. The isolates were further checked for their multidrug resistance pattern and the prevalence of the various antimicrobial resistance genes along with the virulence associated genes which would help in formulating better treatment strategies for the community. Genetic relatedness of these isolates was also determined by analysing their PFGE patterns and plasmid profiling. This research had previously been approved by the institution’s ethics review board. Each isolate was preserved in a 15% glycerol stock that was frozen at -80°C.

3. Antimicrobial susceptibility testing and determination of MIC

Shigella isolates were tested for their susceptibility to various antibiotics using the Kirby-Bauer disc-diffusion method on Mueller-Hinton agar, as recommended by the Clinical and Laboratory Standards Institute [25]. Commercially available discs (Becton Dickinson, BBL): nalidixic acid (NA; 30μg), ciprofloxacin (CIP; 5μg), norfloxacin (NOR; 10μg), ofloxacin (OFX; 5μg), tetracycline (TET; 30μg), ampicillin (AM; 10μg), streptomycin (S; 10μg), trimethoprim-sulfamethoxazole (SXT; 1.25/23.75μg), ceftriaxone (CRO; 30μg) and chloramphenicol (CHL; 30μg) were used in this assay. Following the CLSI standards, we interpreted the data. For a subset of resistant isolates, we used the agar dilution method to determine the CLSI-recommended minimum inhibitory concentrations (MICs) of nalidixic acid, ciprofloxacin, ampicillin, tetracycline, streptomycin, and chloramphenicol. In order to ensure consistent results, we used Escherichia coli ATCC 25922 as a reference strain [25].

4. Preparation of template DNA

Bacterial cells that had been cultured for 24 hours in a volume of 200μl of TE buffer were heated to 100°C for 10 minutes and then stored on ice. After the thermal shock, a centrifuge was used to spin the resulting suspension at 10,000 rpm for 5 minutes. The template DNA for the PCR assay came from about 4 μl of the supernatant.

5. PCR amplification of virulence genes

The genes for virulence (ipaH, ial, set (sHET-1), sen (sHET-2), virF, virB, sat, sigA, sep, and pic) were identified by polymerase chain reaction (PCR) with the primers provided in S1 Table.

6. Determination of integron and AMR gene markers by PCR

The three integrons (intI, intII, and intIII) were identified using PCR techniques. To further categorise the isolates into those with typical or atypical class 1 gene cassettes, we looked for the presence of the qacEΔ1 gene at the 3’ end of the class 1 conserved segment and at the gene cassette within the variable region of class 1 and class 2 integrons. Direct sequencing of the PCR product was used to identify class 1 and class 2 resistance gene cassettes. The BLAST programme was used to compare the obtained sequences to those in the NCBI database, and the results were analysed accordingly.

In order to screen for the presence of specific resistance genes, PCR was performed on MDR Shigella isolates using previously published primers. (S2 Table). Several resistance genes like, β-lactamase genes (blaOXA, blaTEM, blaCTX-M); sulphonamide (sul2) and trimethoprim (dfr1) resistance genes; chloramphenicol (catA) resistance gene; streptomycin (aadA, strA); tetracycline (tetA, tetB) were mainly screened. In addition, the presence of plasmid-mediated quinolone resistance (PMQR) genes (qnrA, qnrB, qnrD, qnrS, and aac-(6’)-1b) was investigated in some quinolone-resistant isolates. The role of topoisomerase mutations in quinolone resistance was investigated by using two or more representative isolates with differing profiles of quinolone resistance. The mutations were found by amplification and sequencing of the quinolone resistance determining regions (QRDRs) of topoisomerase (gyrA, gyrB, parC, and parE) and comparison to Shigella control strain DNA (Accession: NC_004741.1) from the database.

7. Plasmid profiling

Plasmids were extracted from representative isolates using a modified version of the Kado and Liu method [26]. Plasmid profiles were characterised by electrophoresis on an agarose gel with a dilution of 0.8%. After electrophoresis and ethidium bromide staining, the gels were photographed using a Bio-Rad gel documentation system. Using a DNA ladder as a standard, the migration patterns of the unknown plasmids were compared with those of the known plasmids, allowing their molecular weights to be calculated.

8. Analysis of similarity among isolates with the help of plasmid profiling

Dendrograms were constructed using the FPQuest software to show the degree to which the isolates were similar based on their plasmid profiles. The unweighted pair group method (UPGMA analysis) was applied to the matrix similarity coefficients (1.5% position tolerance) to produce a dendrogram with the average linkage method.

9. Molecular typing of isolates by PFGE

Following the PulseNet standard protocol (https://www.cdc.gov/pulsenet/pdf/ecoli-shigella-salmonella-pfge-protocol-508c.pdf), DNA fingerprinting was carried out by PFGE of XbaI digested genomic DNA of the study strains using CHEF DRIII (Bio-Rad). The molecular DNA ladder consisted of XbaI-digested Salmonella enterica serovar Braenderup H9812. Gel images were recorded using a Gel-Documentation system (Bio-Rad), and PFGE profiles were analysed with BioNumerics software (Applied Maths, version 5.0). Similarity between bands was measured using the Dice coefficient, and correlation coefficients between clusters were calculated using the UPGMA method.

10. Statistical analysis

Statistical analysis was performed using Chi-square test for infection rate, age distribution part and Chi-square test for trend was used for calculating trend analysis of seasonality and antimicrobial resistance trend by using STATA v.18.0 (StataCorp LLC., College Station, Texas). A p value of < 0.05 was considered statistically significant.

Results

1. Prevalence of Shigella spp

During the study period, 535 (5.8%) Shigella spp. were isolated from 9,276 enrolled diarrheal cases. The macroscopic characteristics of stools related to Shigellosis have different characteristics like, majority of the infected stools had muciod consistency (48%), 31% was bloody diarrheal stool, 12% was watery diarrhoeal stool, whereas 4% and 5% were semisolid stool and swab respectively. The numbers and percentage of different Shigella serogroups isolated were 407 (76.1%) S. flexneri, 100 (18.7%) S. sonnei, 18 (3.4%) S. boydii, and 10 (1.8%) S. dysenteriae. Table 1 shows the yearly distribution of Shigella. The number of stool specimens collected each year started increasing in 2013 and remained same throughout the study period. The isolation rate of Shigella spp. remained relatively stable during the study period, but in 2013, the rate of isolation decreased drastically. In 2019, the Shigella infection rate reached its peak, while its lowest occurrence was observed in 2013. In fact, approximately 4-fold increase in annual infection rate from 2.2% in 2013 to 9% in 2019 (Fig 1) was noted. There is a significant difference in the isolation rate (p < 0.00001). Fig 2 illustrates the overall monthly isolation of all Shigella spp. during 9 years, the trends in the S. sonnei isolation rate with relation to seasonality show a decreasing trend from 2012 onwards (S1 Fig), i.e., the isolation rates were high during the pre-monsoon season (March–May) and low during the winter season (December–February). S. sonnei showed a slightly reverse trend in the year 2011. No such trend was observed for S. flexneri (S2 Fig).

Table 1. Yearly distribution and infection of Shigella serogroups from stool sample of acute diarrheal patients at ID hospital, 2011–2019.

Year 2011 2012 2013 2014 2015 2016 2017 2018 2019 TOTAL
Total no. of stool specimens 643 967 1184 1135 1195 1266 1254 940 692 9276
S.dysenteriae 1(0.16) 2(0.2) 0(0) 1(0.09) 0(0) 4(0.32) 0(0) 1(0.11) 1(0.14) 10(0.11)
S.flexneri 31(4.82) 58(5.99) 21(1.77) 35(3.08) 46(3.84) 47(3.71) 71(5.66) 48(5.11) 50(7.23) 407(4.39)
S.boydii 0(0) 5(0.52) 2(0.17) 5(0.44) 0(0) 1(0.08) 1(0.08) 1(0.11) 3(0.43) 18(0.19)
S.sonnei 4(0.62) 11(1.14) 3(0.25) 11(0.97) 19(1.59) 12(0.95) 19(1.52) 13(1.38) 8(1.16) 100(1.08)
Total no. isolated 36(5.59) 76(7.86) 26(2.2) 52(4.58) 65(5.44) 64(5.06) 91(7.26) 63(6.70) 62(8.96) 535(5.77)

Fig 1. Distribution of Shigella isolates in patients during 2011 and 2019 in Kolkata, India.

Fig 1

Shigella infection rate of (%): the proportion of shigellosis cases in diarrhea patients.

Fig 2. Seasonal distribution of total shigellosis cases.

Fig 2

The proportion of Shigella cases varied majorly by age groups, with the highest rate being 9% in 6–14 years of age group, followed by 7.2% in >60 years of age group. In addition, the data represented predominance of S. flexneri infection (6.9%) in children aged between 6–14 years (Fig 3). S. sonnei infection dominates in the 6–14-year-old age group (1.9%), followed by <5 years of age (1.8%) (Fig 3). S. flexneri and S. sonnei isolation rates among the 0–5 year age group remained almost similar. Although there was no significant relation with respect to different serotype distribution among the other age groups (p = 0.873). However, the isolation rate of S. sonnei among the different age groups showed a significant variation (p = 0.0001). The isolation percentage among the 0–14 group was much higher than the other age groups. The S. flexneri isolation rate was significantly higher in age groups other than 0–5 years (p = 0.0001). In the case of Shigella spp., the isolation rate among males was slightly higher (56.8%) than that of female patients (43.2%).

Fig 3. Demographic features of Shigella cases.

Fig 3

Percentage (%): the proportion of Shigella cases by different groups of ages.

During the entire duration of the study, S. flexneri was the most predominant seroroup, among which serotype 2a (54%) had the highest rate, followed by serotypes 3a, 4a, and 1b, with prevalence rates of 21%, 8%, and 5%, respectively (Fig 4). Notably, 13 (4.2%) S. flexneri were designated as S. flexneri untypable (UT), as they only agglutinated with polyvalent type B antiserum; further serotyping of these isolates could not be completed with commercially available Shigella antisera.

Fig 4. The serotypes of S. flexneri species from 2011 to 2019 in Kolkata, India.

Fig 4

2. Antimicrobial resistance in Shigella spp

A significant portion of isolates exhibited resistance to nalidixic acid (91.8%), ciprofloxacin (83.4%), ofloxacin (81.9%), norfloxacin (79.8%), tetracycline (75.5%), co-trimoxazole (65.6%), and streptomycin (69.9%). For chloramphenicol and ampicillin, the Shigella isolates showed a medium range of resistance (46.3% and 54.4%, respectively). For the third generation cephalosporin, and ceftriaxone, the susceptibility rate of the isolates was about 94%. All the isolates remained susceptible to the carbapenem group of antibiotics (Table 2). In S. dysenteriae, nalidixic acid and streptomycin resistance were high (80% and 70%, respectively). However, all S. dysenteriae isolates were susceptible to ceftriaxone.

Table 2. The percentages of resistance among different Shigella serotypes to various antimicrobial agents.

Number resistant to antimicrobials (%)
Antimicrobial agents Total (n = 535) S. dysenteriae (n = 10) S. flexneri (n = 407) S. boydii (n = 17) S. sonnei (n = 100)
Nalidixic Acid 491(91.77) 8(80) 373(91.64) 11(64.70) 99(99)
Ciprofloxacin 446(83.36) 2(20) 342(84.02) 3(17.65) 99(99)
Norfloxacin 427(79.81) 1(10) 331(81.33) 3(17.65) 92(92)
Ofloxacin 438(81.87) 1(10) 340(83.54) 2(11.76) 95(95)
Tetracycline 404(75.51) 5(50) 329(80.84) 3(17.65) 67(67)
Ampicillin 291(54.39) 5(50) 262(64.37) 11(64.70) 13(13)
Ceftriaxone 32(5.98) 0(0) 25(6.14) 1(5.88) 6(6)
Co-trimoxazole 351(65.60) 5(50) 259(63.63) 10(58.82) 77(77)
Streptomycin 374(69.90) 7(70) 271(66.58) 16(94.12) 80(80)
Chloramphenicol 248(46.35) 3(30) 240(58.97) 1(5.88) 4(4)

Almost 80% of S. flexneri had multidrug resistance, whereas only 6.1% were resistant to ceftriaxone. S. boydii was susceptible to most of the tested drugs except streptomycin, nalidixic acid, ampicillin, and co-trimoxazole, with resistances of 94.1%, 64.7%, 64.7%, and 58.8%, respectively. On the other hand, S. sonnei isolates showed 70–90% resistance to all tested antimicrobials, except ampicillin, chloramphenicol, and ceftriaxone (13%, 4%, and 6%, respectively).

During this 9-year study period, the resistance rate of S. flexneri to ampicillin and ceftriaxone increased from 47.9% to 69.2% and 3.2% to 9.6%, respectively, whereas that of S. sonnei increased from 0% to 17.1% and 0% to 6.9%, respectively. There was a notable increase in resistance to ciprofloxacin (p = 0.000), ofloxacin (p = 0.058), ampicillin (p = 0.0088) and ceftriaxone (p = 0.0106). There is a decreasing trend of resistance to co-trimoxazole. While there was no significant change in the S. sonnei AMR trend, S. flexneri isolates showed significant changes in the resistance for ampicillin, co-trimoxazole, and ceftriaxone (p = 0.0001, 0.0004, and 0.0105, respectively).

The MIC range for different serotypes is shown in Table 3. Several types of resistance profiles were observed, and the common resistance profiles have been depicted in Table 4. The majority of the Shigella isolates demonstrated resistance to multiple categories of antibiotics. The most common resistance profile of the isolates confered resistance to almost five groups of antibiotics, like aminoglycosides, tetracycline, antifolate, fluoroquinolones, and β-lactam.

Table 3. Minimum inhibitory concentrations MIC of antimicrobial agents for Shigella spp.

Antimicrobial agent Break point
(μg/ml)
S. dysenteriae S. flexneri S. boydii S. sonnei
Range MIC50
(μg/ml)
MIC90
(μg/ml)
MIC50
(μg/ml)
MIC90
(μg/ml)
MIC50
(μg/ml)
MIC90
(μg/ml)
MIC50
(μg/ml)
MIC90
(μg/ml)
Ampicillin ≥32 32–512 >512 >512 >256-<512 >512-<1024 >128-<256 >512 >32-<64 >32-<64
Tetracycline ≥16 16–256 >64-<128 >64-<128 >64-<128 >64-<128 >16-<32 >32-<64 >64-<128 >64-<128
Ciprofloxacin ≥4 4–64 >4-<8 >4-<8 >4-<8 >16-<32 <4 <4 >4-<8 >8-<16
Nalidixic Acid ≥32 32–1024 >128-<256 >128-<256 >1024 >1024 >32-<64 >256-<512 >512-<1024 >512-<1024
Streptomycin - 64–1024 >64-<128 >64-<128 >512-<1024 >1024 >64-<128 >64-<128 >256-<512 >1024
Chloramphenicol ≥32 32–512 <32 <32 >32-<64 >64-<128 <32 >32-<64 >16-<32 >32-<64

Table 4. Most common Resistance profile of Shigella isolates of ID hospital during 2011–2019.

Sl No Resistance profile Total no. of Isolates 2011 2012 2013 2014 2015 2016 2017 2018 2019
I NA/CIP/NOR/OFX/TET/AM/SXT/S/CHL 100 12 22 3 7 11 12 12 10 11
II NA/CIP/NOR/OFX/TET/SXT/S 70 5 11 2 7 13 9 14 5 4
III NA/CIP/NOR/OFX/TET/AM/S/CHL 57 0 4 0 6 5 3 21 11 7
IV NA/CIP/NOR/OFX/TET/SXT/S/CHL 38 8 10 3 2 1 1 7 2 4
V NA/CIP/NOR/OFX/TET/AM/SXT/S 22 5 0 0 1 7 1 2 2 4
VI NA/CIP/NOR/OFX 17 1 2 1 1 3 2 3 2 2
VII NA/CIP/NOR/OFX/S 14 0 1 1 0 0 3 5 1 3

3. Detection of virulence genes

About 51% of the isolates harbouredial, which was encoded in an invasive plasmid. virF and virB were found in 50.9% and 40.8% of the isolates, respectively. The chromosomally encoded set was present in 39.5% of the tested isolates, whereas the plasmid-encoded sen was found in 48.4% of the isolates. The secreted autotransporter toxin-encoded sat gene was found in 52.2% of the isolates, and other serine protease autotransporter toxin encoding genes like sigA, pic, and sepA were present in 63%, 35.7%, and 53.5% of the isolates, respectively.

4. Characterisation of integrons and AMR genes

A total of 28.6%, 26.12%, and 40.13% of the Shigella isolates harboured intlI, intlII, and both intlI/intlII genes, respectively. No class intIII was noted in any of the Shigella isolates. The prevalence of intI, intII and both intI/intII genes in different serogroups of Shigella spp. is shown in Fig 5.

Fig 5. Distribution of different intrgrons in different serogroups of Shigella.

Fig 5

The presence of atypical class 1integrons and typical class 1 integrons was detected in 17.8% and 5% of the Shigella isolates, respectively. While 17.4% of the isolates were found to carry both class 1 typical and class 1 atypical integrons. Interestingly, different types of class 1 integrons co-existed with class 2 integrons, with 16.6% of the isolates carrying the combination of atypical class 1/class 2 integrons, while only 7% of the isolates had typical class 1/class 2 integrons (Fig 6).

Fig 6. Distribution of different classes of integrons among tested isolates.

Fig 6

The strains with typical integrons showed two different sizes of amplicons (500 bp and >2.5 kb). On sequencing, the 500 bp of the class 1 integron did not show any of the antimicrobial resistance gene cassettes. Atypical class 1 integrons had 2 kb and 2.4 kb amplicon sizes, and upon sequencing, the 2kb had 100% nucleotide identity with GenBank accession no. GQ214137 of S. flexneri with the AMR gene cassettes dfrA1-aadA, and blaOXA-aadA gene cassettes with full sequence similarity with GenBank accession no. KX817769 was carried by 2.4 kb variable region of the atypical class 1 integron. Two different sizes of class 2 gene cassettes were found among the tested isolates. The 1.4 kb cassette was observed mainly in S. sonnei, whereas the 2.2 kb region was found in other Shigella spp. The former had a sequence similarity dfrA1-sat (GenBank accession no. KX817766), and the later shared the dfrA1-sat-aadA sequence similarity (GenBank accession no. KX817767).

The presence of AMR genes was screened among isolates that were resistant to one or more antimicrobials. Among these, 69.4% were positive for blaOXA-1, whereas only 12.3% were positive for blaTEM-9.Whereas, among 32 ceftriaxone resistance strains 37.5% were blaCTX-M positive. tetA and tetB genes were respectively detected in 13.9% and 77.9% of the isolates that confer resistance to tetracycline. qnrB (4.6%), qnrS (3.8%),and aac (6’)1b (0.8%) were found to be responsible for fluoroquinolone resistance. Mostly, quinolone resistance was associated with gyrA (S83L, D87N, H211Y) and/or parC (S80I) mutations (Table 5). No mutation was seen in the gyrB and parE. Other AMR-encoding genes like strA and aadA1A for streptomycin and dfrA1 and sul2 for co-trimoxazole were detected in 52.4%, 55.8%, 84%, and 61.9%, respectively, whereas the prevalence of the catA, responsible for chloramphenicol resistance was found 46.1% of the isolates.

Table 5. Mutations in quinolone resistance determining regions (QRDR) of representative quinolone resistant Shigella isolates.

Strain Strain ID Quinolone resistance MIC CIP(μg/ml) GyrA ParC
S. flexneri 2a IDH10994 NA, CIP, NOR, OFX 4–8 S83->L
D87->N
H211->Y
S80->I
S. sonnei IDH 8898 NA, CIP, NOR, OFX 8–16 S83->L
D87->N
S80->I
S. flexneri 2a IDH 10932 NA, CIP, NOR, OFX 16–32 S83->L
D87->N
H211->Y
S80->I
S. dysenteriae IDH 9602 NA, CIP, NOR, OFX 2–4 S83->L -
S. sonnei IDH 6701 NA, CIP, NOR, OFX 0.5–1 S83->L
D87->G
S80->I

5. Plasmid profiling

The dendrogram-based genetic similarity analysis of representative Shigella spp. was analysed. There was a similarity of 77.6% among the S. boydii group (S3 Fig), whereas the similarities were less among S. flexneri and S. sonnei (18% and 25.6%, respectively) (S4 and S5 Figs), indicating the diversity of plasmid patterns.

6. Molecular typing by PFGE

The XbaI DNA fragments obtained in the PFGE were analysed with the corresponding species: S. dysenteriae (Fig 7), S. flexneri (Fig 8), S. boydii (Fig 9) and S. sonnei (Fig 10). PFGE analysis of S. dysenteriae isolates revealed two clusters with approximately 70% similarity within them (Fig 7). When S. flexneri 2a isolates of different years and AMR profiles were compared, there were two clusters present with 85% similarity (Fig 8). The IDH 12673 isolate was identified as belonging to a different clone with only 74% similarity to other S. flexneri 2a. Among the 9 S. boydii isolates, 6 strains formed a distinct cluster with 76% similarity to another cluster of 3 isolates (Fig 9). S. sonnei had two clusters with 85% similarity. Among 32 representative isolates, 18 belonged to the first cluster, whereas another 14 strains belonged to the second cluster and shared 90–100% similarity among the isolates (Fig 10). Only IDH 7727 shows a unique banding pattern with 83% similarity to the other isolates.

Fig 7. XbaI-PFGE profiles of with dendrogram showing percentage similarity of S. dysenteriae isolates.

Fig 7

Fig 8. XbaI-PFGE profiles of with dendrogram showing percentage similarity of S. flexneri isolates.

Fig 8

Fig 9. XbaI-PFGE profiles of with dendrogram showing percentage similarity of S. boydii isolates.

Fig 9

Fig 10. XbaI-PFGE profiles of with dendrogram showing percentage similarity of S. sonnei isolates.

Fig 10

Discussion

The frequency of Shigella isolation, the species distribution, and the antimicrobial resistance pattern were examined in this study. The total isolation rate was 5.8%, with S. flexneri (76.1%) being the most dominant one, followed by S. sonnei (18.7%), S. boydii (3.4%), and S. dysenteriae (1.8%). A similar trend has been reported from Bangladesh and China [27,28]. Our finding indicates that the overall isolation rate of Shigella spp. from Kolkata remains 6–7% and the prevalence of its species remained the same as reported before from the same region [23,29]. Two investigations conducted in Kolkata between 2001 and 2007 [30,31] and one conducted in North Karnataka over a period of 12 years [32] found that the frequency of S. dysenteriae was 2.1% greater than that of S. boydii, which slightly differs from our findings. Numerous investigations around the world [3338] revealed that the most common serotype was S. flexneri 2a, which was also observed in this study. We found that the children belonging to the age group 6–14 years had the largest proportion of being infected with S. flexneri or S. sonnei. A study conducted in Asia and Africa indicated that children aged below 5 years are mostly infected with Shigella spp. [39,40]. One plausible explanation for the lack of cases in children younger than 5 years old in the current study might be due to the fact that children with mild to moderate diarrhea would have received treatment at home or in other hospitals in the city. Like in other reports [41,42], the ratio of male to female Shigella-infected cases is similar.

Shigella pathogenesis is the result of a combination of several different virulence factors. Almost all the species of Shigella had plasmid-borne inv and also the chromosomally encoded virulence factors.

In 2017, the WHO highlighted the urgent need for new antibiotics on a list of priority pathogens, and Shigella was among them. More than 60% of the isolates in our investigation were resistant to fluoroquinolone, aminoglycoside, and folate inhibitory groups, which matched with other global reports [20,22,4345]. However, S. sonnei was more sensitive to ampicillin and chloramphenicol than S. flexneri. Ceftriaxone and azithromycin are currently recommended by the WHO for the treatment of fluoroquinolone-resistant Shigella infections. Our finding indicates that Shigella was highly susceptible to cephalosporin, suggesting that this drug could be a better choice for empirical treatment.

According to a CDC’s report, approximately 77,000 drug-resistant Shigella infections occur annually, making this pathogen categorized as a serious threat [46]. Determining the role of genetic elements such as integrons, plasmids, and chromosomally carried topoisomerase mutations in the development of highly multi-drug-resistant phenotypes is therefore crucial. Certain Shigella isolates have developed resistance to antibiotics like trimethoprim and spectinomycin because of integrons [47,48]. Previous studies have indicated that a majority of the isolates examined had an atypical class 1 integron, but that a few had the typical class 1 integron [49]. In class two integrons, dfrA1-sat and dfrA1-sat-aadA are the most common gene cassettes identified in S. sonnei and S. flexneri, respectively. Class 2 integrons seem to be the distinctive feature of these two Shigella serogroups.

The mobile genetic elements, including integrons and plasmids are playing a significant role in the spread of AMR among bacteria. These bacteria frequently have blaTEM, which imparts resistance to penicillin and other β-lactam antibiotics [50,51]. Nevertheless, the OXA-type β-lactam, with significant hydrolytic activity against oxacillin and cloxacillin, frequently transmits resistance to ampicillin and cephalothin. Similar to the other studies, our findings show that 69.4% of the isolates tested positive for blaOXA-1 and 12.3% for blaTEM [21,52]. In accordance with earlier results [52], tet(B) was more frequent than tet(A). Streptomycin resistance was largely attributed to strA, but aadA1 also appears to play a strong role. Quinolone resistance is typically caused by mutations in QRDR region, efflux pump activity, and PMQR genes [53]. In this study, several mutations in the QRDR have been identified, irrespective of MIC. Mutations in the gyrA (S83, D87, H211) and parC (S80) have been frequently reported from India as well as globally [54]. Although no mutation was noted in gyrB gene in our study whereas only one single mutation at 517 position is reported from China [54]. An association of broader range of resistance to different quinolone was also observed with mutations in both topoisomerases [55].

Our study has identified the presence of the PMQR genes qnrB, qnrS, and aac(6’)1b that are responsible for fluoroquinolone resistance. Empirical treatments rely heavily on antibiotic resistance patterns since it can also be used as a typing system and AMR determinants spreading indicator as well [19]. Due to the absence of diversity in the susceptibility patterns, we were unable to use the AMR pattern as an epidemiological marker.

Molecular epidemiological investigations, comparing plasmid and PFGE profiles, are valuable tools for determining the probable relatedness among clinical isolates of a specific bacterial species [5658]. Our study ascertained that the clonal relatedness among S. dysenteriae isolates was 70%, which is almost similar to previous reports from Kolkata [23,49,59]. In S. flexneri, 85% similarity was noted, which is also similar to other findings [23,5962]. As shown in a previous study from Kolkata, representative isolates of S. boydii had 76% similarity [49]. The clonal relatedness of S. sonnei from different countries reproduces a parallel observation like our study outcome [21,27,52,6264]. As evidenced by this study, multiple clones were identified in different serotypes, confirming the existence of diverse origins among Shigella spp.

Limitations

There are a number of constraints that have been identified during the nine-year monitoring period. Local administration, individuals at risk, government agencies, healthcare providers at all levels, and healthcare providers at the federal and state levels must all work together continuously to maintain comprehensive sentinel surveillance. Since this bacterium can be transmitted from person to person through the faecal-oral route and can be found in both water and food, it has been extremely difficult to persuade people of the importance of public health. Further complications such as missed diagnoses, drug resistance, and limited treatment options result from the unsupervised use of antibiotics for diarrhea. One possible explanation for the fluctuating reporting of cases over time is that healthcare workers and other vulnerable populations are not consistently informed about this bacterium. The potential underreporting of subclinical and distant cases is a noteworthy worry associated with this surveillance. Strains prevalent in rural areas are not included in the study because it only includes cases admitted to the ID hospital as referral patients. The study sheds light on the most prevalent strains in Kolkata, but it doesn’t go far enough to compare their clonality to other parts of the Indian subcontinent.

Conclusion

Due to overcrowding and poor sanitation, shigellosis is mainly found in developing nations. The species S. flexneri and S. sonnei were found most frequently, with S. dysenteriae being an exception. According to the World Health Organization’s guidelines (2016), the risk of death from Shigellosis is higher in infants, nonbreastfed children, children recovering from measles, malnourished children, and adults older than 50 years. The two main Shigella species, according to our results, caused shigellosis in different age groups. Additionally, this study helps with virulence profiling of Shigella strains and serotype distribution profiling, both of which are important for tracking new variants and patterns of isolates in our region; many questions remain about this notorious and evasive bacterial pathogen. As the research progressed, resistance to cotrimoxazole decreased while resistance to anti-shigellosis medications increased. There has been a shift in the antibiotic resistance pattern and the frequency of certain Shigella species at various points in time. In order to select effective medications for empirical treatment, it is essential to thoroughly investigate the antibiotic susceptibility pattern and the precise geographical source of antibiotic resistance. An enormous problem could arise from the unchecked use of antibiotics in general, since this would hasten the development of multi-resistant bacteria that pose a threat to current treatment methods. Therefore, it is essential to learn how resistance works and devise methods for eliminating it. Public health measures, such as clean water and sanitation, as well as public health education, are necessary to reduce the morbidity and mortality caused by diarrhea in our nation. Other important factors include newer antimicrobials and cost-effective vaccines. In order to better understand local circulating strains and their phenotypic and genotypic traits, it is recommended that mandatory surveillance be expanded to include shigellosis in both hospitals and the community. Together, these initiatives have the potential to stem the tide of antimicrobial-resistant Shigella from spreading over the world. We conclude that antimicrobial treatment should be revised on a regular basis according to surveillance data.

Supporting information

S1 Table. Primer list for virulence gene.

(DOCX)

pntd.0011964.s001.docx (22.4KB, docx)
S2 Table. Primer list for antimicrobial resistance gene.

(DOCX)

pntd.0011964.s002.docx (35.3KB, docx)
S1 Fig. Trends for S. sonnei isolation rate with relation to seasonality.

(TIF)

pntd.0011964.s003.tif (365.4KB, tif)
S2 Fig. The trends for S.flexneri isolation rate with relation to seasonality.

(TIF)

pntd.0011964.s004.tif (361KB, tif)
S3 Fig. Similarity among the Shigella boydiiisolateson the basis of their plasmid profiles.

(TIF)

pntd.0011964.s005.tif (96.4KB, tif)
S4 Fig. Similarity among the Shigella flexneri 2a isolates on the basis of their plasmid profiles.

(TIF)

pntd.0011964.s006.tif (589.4KB, tif)
S5 Fig. Similarity among the Shigella sonnei isolates on the basis of their plasmid profiles.

(TIF)

pntd.0011964.s007.tif (424.5KB, tif)

Acknowledgments

We are thankful to Mr. Mukul Roy and Mr. Biswajit Sharma for technical assistance in the PFGE experiment.

Data Availability

All relevant data are within the manuscript and its Supporting information files. The sequences submitted in the GenBank are available with accession number PP196524 to PP196533.

Funding Statement

This project was partially supported by the program of the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID), JP23wm0125004 and JP23wm0225021 from Ministry of Education, Culture, Sports, Science and Technology in Japan (MEXT), and Japan Agency for Medical Research and Development (AMED). Grant recipient was SM. This research was also supported in part by Indian Council of Medical Research (ICMR), Govt. of India and the National Institute of Infectious Diseases (NIID), Japan (grant No.: JP23fk0108683 from AMED) to AKM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Nüesch-Inderbinen M, Heini N, Zurfluh K, Althaus D, Hächler H, Stephan R. Shigella Antimicrobial Drug Resistance Mechanisms, 2004–2014. Emerg Infect Dis. 2016;22: 1083–1085. doi: 10.3201/eid2206.152088 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18: 318–327. doi: 10.1016/S1473-3099(17)30753-3 [DOI] [PubMed] [Google Scholar]
  • 3.Ghosh S, Pazhani GP, Niyogi SK, Nataro JP, Ramamurthy T. Genetic characterization of Shigella spp. isolated from diarrhoeal and asymptomatic children. J Med Microbiol. 2014;63: 903–910. doi: 10.1099/jmm.0.070912-0 [DOI] [PubMed] [Google Scholar]
  • 4.Venkatesan MM, Ranallo RT. Live-attenuated Shigella vaccines. Expert Rev Vaccines. 2006;5: 669–686. doi: 10.1586/14760584.5.5.669 [DOI] [PubMed] [Google Scholar]
  • 5.Hussen S, Mulatu G, Yohannes Kassa Z. Prevalence of Shigella species and its drug resistance pattern in Ethiopia: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2019;18: 22. doi: 10.1186/s12941-019-0321-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Schroeder GN, Hilbi H. Molecular Pathogenesis of Shigella spp.: Controlling Host Cell Signaling, Invasion, and Death by Type III Secretion. Clin Microbiol Rev. 2008;21: 134–156. doi: 10.1128/CMR.00032-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Taneja N, Mewara A. Shigellosis: Epidemiology in India. Indian J Med Res. 2016;143: 565–576. doi: 10.4103/0971-5916.187104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Williams PCM, Berkley JA. Guidelines for the treatment of severe acute malnutrition: a systematic review of the evidence for antimicrobial therapy. Paediatr Int Child Health. 2018;38: S32–S49. doi: 10.1080/20469047.2017.1409453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fan W, Qian H, Shang W, Ying C, Zhang X, Cheng S, et al. Low distribution of genes encoding virulence factors in Shigella flexneri serotypes 1b clinical isolates from eastern Chinese populations. Gut Pathogens. 2017;9: 76. doi: 10.1186/s13099-017-0222-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Casabonne C, González A, Aquili V, Balagué C. Prevalence and Virulence Genes of Shigella spp. Isolated from Patients with Diarrhea in Rosario, Argentina. Jpn J Infect Dis. 2016;69: 477–481. doi: 10.7883/yoken.JJID.2015.459 [DOI] [PubMed] [Google Scholar]
  • 11.Parham NJ, Pollard SJ, Desvaux M, Scott-Tucker A, Liu C, Fivian A, et al. Distribution of the Serine Protease Autotransporters of the Enterobacteriaceae among Extraintestinal Clinical Isolates of Escherichia coli. J Clin Microbiol. 2005;43: 4076–4082. doi: 10.1128/JCM.43.8.4076-4082.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.European Centre for Disease Prevention and Control. Annual epidemiological report 2013: reporting on 2011 surveillance data and 2012 epidemic intelligence data. LU: Publications Office; 2013. https://data.europa.eu/doi/10.2900/13174
  • 13.Ashkenazi S. Shigella infections in children: new insights. Semin Pediatr Infect Dis. 2004;15: 246–252. doi: 10.1053/j.spid.2004.07.005 [DOI] [PubMed] [Google Scholar]
  • 14.Rowe-Magnus DA, Guerout A-M, Mazel D. Bacterial resistance evolution by recruitment of super-integron gene cassettes. Mol Microbiol. 2002;43: 1657–1669. doi: 10.1046/j.1365-2958.2002.02861.x [DOI] [PubMed] [Google Scholar]
  • 15.Al-Nimri S, Miller WA, Byrne BA, Guibert G, Chen L. A unified approach to molecular epidemiology investigations: tools and patterns in California as a case study for endemic shigellosis. BMC Infectious Diseases. 2009;9: 184. doi: 10.1186/1471-2334-9-184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, et al. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol. 2013;47: 12–20. doi: 10.1097/MCG.0b013e31826df662 [DOI] [PubMed] [Google Scholar]
  • 17.Porter CK, Thura N, Ranallo RT, Riddle MS. The Shigella human challenge model. Epidemiol Infect. 2013;141: 223–232. doi: 10.1017/S0950268812001677 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Das A, Natarajan M, Mandal J. The Emergence of Quinolone Resistant Shigella sonnei, Pondicherry, India. PLoS One. 2016;11: e0160290. doi: 10.1371/journal.pone.0160290 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Farshad S, Sheikhi R, Japoni A, Basiri E, Alborzi A. Characterization of Shigella Strains in Iran by Plasmid Profile Analysis and PCR Amplification of ipa Genes. J Clin Microbiol. 2006;44: 2879–2883. doi: 10.1128/JCM.00310-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Heffernan H, Woodhouse R, Hewison C, Sherwood J. Antimicrobial resistance among Shigella in New Zealand. N Z Med J. 2018;131: 56–62. [PubMed] [Google Scholar]
  • 21.Wang Y, Ma Q, Hao R, Zhang Q, Yao S, Han J, et al. Antimicrobial resistance and genetic characterization of Shigella spp. in Shanxi Province, China, during 2006–2016. BMC Microbiology. 2019;19: 116. doi: 10.1186/s12866-019-1495-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Gaufin T, Blumenthal J, Ramirez-Sanchez C, Mehta S, Pride DT, Fierer J, et al. Antimicrobial-Resistant Shigella spp. in San Diego, California, USA, 2017–2020. Emerg Infect Dis. 2022;28: 1110–1116. doi: 10.3201/eid2806.220131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ghosh S, Pazhani GP, Chowdhury G, Guin S, Dutta S, Rajendran K, et al. Genetic characteristics and changing antimicrobial resistance among Shigella spp. isolated from hospitalized diarrhoeal patients in Kolkata, India. J Med Microbiol. 2011;60: 1460–1466. doi: 10.1099/jmm.0.032920-0 [DOI] [PubMed] [Google Scholar]
  • 24.Nair GB, Ramamurthy T, Bhattacharya MK, Krishnan T, Ganguly S, Saha DR, et al. Emerging trends in the etiology of enteric pathogens as evidenced from an active surveillance of hospitalized diarrhoeal patients in Kolkata, India. Gut Pathog. 2010;2: 4. doi: 10.1186/1757-4749-2-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
  • 26.Kado CI, Liu ST. Rapid procedure for detection and isolation of large and small plasmids. J Bacteriol. 1981;145: 1365–1373. doi: 10.1128/jb.145.3.1365-1373.1981 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ud-Din AIMS, Wahid SUH, Latif HA, Shahnaij M, Akter M, Azmi IJ, et al. Changing trends in the prevalence of Shigella species: emergence of multi-drug resistant Shigella sonnei biotype g in Bangladesh. PLoS One. 2013;8: e82601. doi: 10.1371/journal.pone.0082601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yang H, Chen G, Zhu Y, Liu Y, Cheng J, Hu L, et al. Surveillance of Antimicrobial Susceptibility Patterns among Shigella Species Isolated in China during the 7-Year Period of 2005–2011. Ann Lab Med. 2013;33: 111–115. doi: 10.3343/alm.2013.33.2.111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Dutta S, Ghosh A, Ghosh K, Dutta D, Bhattacharya SK, Nair GB, et al. Newly Emerged Multiple-Antibiotic-Resistant Shigella dysenteriae Type 1 Strains in and around Kolkata, India, Are Clonal. Journal of Clinical Microbiology. 2003;41: 5833. doi: 10.1128/JCM.41.12.5833-5834.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Pazhani GP, Ramamurthy T, Mitra U, Bhattacharya SK, Niyogi SK. Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India. Epidemiol Infect. 2005;133: 1089–1095. doi: 10.1017/S0950268805004498 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Nandy S, Mitra U, Rajendran K, Dutta P, Dutta S. Subtype prevalence, plasmid profiles and growing fluoroquinolone resistance in Shigella from Kolkata, India (2001–2007): a hospital-based study. Tropical Medicine & International Health. 2010;15: 1499–1507. doi: 10.1111/j.1365-3156.2010.02656.x [DOI] [PubMed] [Google Scholar]
  • 32.Jain PA, Kulkarni RD, Dutta S, Ganavali AS, Kalabhavi AS, Shetty PC, et al. Prevalence and antimicrobial profile of Shigella isolates in a tertiary care hospital of North Karnataka: A 12-year study. Indian J Med Microbiol. 2020;38: 101–108. doi: 10.4103/ijmm.IJMM_20_107 [DOI] [PubMed] [Google Scholar]
  • 33.Mamatha B, Pusapati BR, Rituparna C. Changing patterns of antimicrobial susceptibility of Shigella serotypes isolated from children with acute diarrhea in Manipal, South India, a 5 year study. Southeast Asian J Trop Med Public Health. 2007;38: 863–866. [PubMed] [Google Scholar]
  • 34.Bhattacharya D, Bhattacharya H, Thamizhmani R, Sayi DS, Reesu R, Anwesh M, et al. Shigellosis in Bay of Bengal Islands, India: clinical and seasonal patterns, surveillance of antibiotic susceptibility patterns, and molecular characterization of multidrug-resistant Shigella strains isolated during a 6-year period from 2006 to 2011. Eur J Clin Microbiol Infect Dis. 2014;33: 157–170. doi: 10.1007/s10096-013-1937-2 [DOI] [PubMed] [Google Scholar]
  • 35.Khaghani S, Shamsizadeh A, Nikfar R, Hesami A. Shigella flexneri: a three-year antimicrobial resistance monitoring of isolates in a Children Hospital, Ahvaz, Iran. Iran J Microbiol. 2014;6: 225–229. [PMC free article] [PubMed] [Google Scholar]
  • 36.Cui X, Wang J, Yang C, Liang B, Ma Q, Yi S, et al. Prevalence and antimicrobial resistance of Shigella flexneri serotype 2 variant in China. Front Microbiol. 2015;6: 435. doi: 10.3389/fmicb.2015.00435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Liu H, Zhu B, Qiu S, Xia Y, Liang B, Yang C, et al. Dominant serotype distribution and antimicrobial resistance profile of Shigella spp. in Xinjiang, China. PLoS One. 2018;13: e0195259. doi: 10.1371/journal.pone.0195259 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Das A, Mandal J. Extensive inter-strain diversity among clinical isolates of Shigella flexneri with reference to its serotype, virulence traits and plasmid incompatibility types, a study from south India over a 6-year period. Gut Pathogens. 2019;11: 33. doi: 10.1186/s13099-019-0314-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. The Lancet. 2013;382: 209–222. doi: 10.1016/S0140-6736(13)60844-2 [DOI] [PubMed] [Google Scholar]
  • 40.Zhao Z, Chen Q, Wang Y, Chu M, Hu Q, Hannah MN, et al. Relative transmissibility of shigellosis among different age groups: A modeling study in Hubei Province, China. PLoS Negl Trop Dis. 2021;15: e0009501. doi: 10.1371/journal.pntd.0009501 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Karacan C, Tavil B, Topal Y, Zorlu P, Tayman C. Evaluation of shigellosis in a Turkish children’s hospital. Pediatr Int. 2007;49: 589–592. doi: 10.1111/j.1442-200X.2007.02425.x [DOI] [PubMed] [Google Scholar]
  • 42.Mook P, Gardiner D, Kanagarajah S, Kerac M, Hughes G, Field N, et al. Use of gender distribution in routine surveillance data to detect potential transmission of gastrointestinal infections among men who have sex with men in England. Epidemiol Infect. 2018;146: 1468–1477. doi: 10.1017/S0950268818001681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Peirano G, Souza F dos S, Rodrigues D dos P. Frequency of serovars and antimicrobial resistance in Shigella spp. from Brazil. Mem Inst Oswaldo Cruz. 2006;101: 245–250. doi: 10.1590/s0074-02762006000300003 [DOI] [PubMed] [Google Scholar]
  • 44.Pakbin B, Amani Z, Allahyari S, Mousavi S, Mahmoudi R, Brück WM, et al. Genetic diversity and antibiotic resistance of Shigella spp. isolates from food products. Food Sci Nutr. 2021;9: 6362–6371. doi: 10.1002/fsn3.2603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Phiri AFND, Abia ALK, Amoako DG, Mkakosya R, Sundsfjord A, Essack SY, et al. Burden, Antibiotic Resistance, and Clonality of Shigella spp. Implicated in Community-Acquired Acute Diarrhoea in Lilongwe, Malawi. Trop Med Infect Dis. 2021;6: 63. doi: 10.3390/tropicalmed6020063 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.); 2019 Nov.
  • 47.Gassama Sow A, Diallo MH, Gatet M, Denis F, Aïdara-Kane A, Ploy M-C. Description of an unusual class 2 integron in Shigella sonnei isolates in Senegal (sub-Saharan Africa). Journal of Antimicrobial Chemotherapy. 2008;62: 843–844. doi: 10.1093/jac/dkn264 [DOI] [PubMed] [Google Scholar]
  • 48.Chang C-Y, Lu P-L, Lin C-C, Lee T-M, Tsai M-Y, Chang L-L. Integron types, gene cassettes, antimicrobial resistance genes and plasmids of Shigella sonnei isolates from outbreaks and sporadic cases in Taiwan. J Med Microbiol. 2011;60: 197–204. doi: 10.1099/jmm.0.022517-0 [DOI] [PubMed] [Google Scholar]
  • 49.Rajpara N, Nair M, Chowdhury G, Mukhopadhyay AK, Ramamurthy T, Niyogi SK, et al. Molecular analysis of multidrug resistance in clinical isolates of Shigella spp. from 2001–2010 in Kolkata, India: role of integrons, plasmids, and topoisomerase mutations. Infect Drug Resist. 2018;11: 87–102. doi: 10.2147/IDR.S148726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Bradford PA. Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin Microbiol Rev. 2001;14: 933–951. doi: 10.1128/CMR.14.4.933-951.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Barlow M, Hall BG. Experimental prediction of the natural evolution of antibiotic resistance. Genetics. 2003;163: 1237–1241. doi: 10.1093/genetics/163.4.1237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Pazhani GP, Niyogi SK, Singh AK, Sen B, Taneja N, Kundu M, et al. Molecular characterization of multidrug-resistant Shigella species isolated from epidemic and endemic cases of shigellosis in India. J Med Microbiol. 2008;57: 856–863. doi: 10.1099/jmm.0.2008/000521-0 [DOI] [PubMed] [Google Scholar]
  • 53.Prof Atta-ur-Rahman, Iqbal Choudhary M, editors. Therapeutic Limitations due to Antibiotic Drug Resistance: Road to Alternate Therapies. Frontiers in Anti-Infective Drug Discovery. BENTHAM SCIENCE PUBLISHERS; 2014. pp. 72–141. [Google Scholar]
  • 54.Ranjbar R, Farahani A. Shigella: Antibiotic-Resistance Mechanisms And New Horizons For Treatment. Infect Drug Resist. 2019;12: 3137–3167. doi: 10.2147/IDR.S219755 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Ding J, Ma Y, Gong Z, Chen Y. [A study on the mechanism of the resistance of Shigellae to fluoroquinolones]. Zhonghua Nei Ke Za Zhi. 1999;38: 550–553. [PubMed] [Google Scholar]
  • 56.Ribot EM, Fair MA, Gautom R, Cameron DN, Hunter SB, Swaminathan B, et al. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog Dis. 2006;3: 59–67. doi: 10.1089/fpd.2006.3.59 [DOI] [PubMed] [Google Scholar]
  • 57.Li S, Wang J, Wei X, Liu Y, You L, Luo X, et al. Molecular Characterization of Shigella sonnei: An Increasingly Prevalent Etiologic Agent of Shigellosis in Guizhou Province, Southwest of China. PLoS One. 2016;11: e0156020. doi: 10.1371/journal.pone.0156020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Zhu Z, Wang W, Cao M, Zhu Q, Ma T, Zhang Y, et al. Virulence factors and molecular characteristics of Shigella flexneri isolated from calves with diarrhea. BMC Microbiol. 2021;21: 214. doi: 10.1186/s12866-021-02277-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Dutta S, Jain P, Nandy S, Matsushita S, Yoshida S-I. Molecular characterization of serologically atypical provisional serovars of Shigella isolates from Kolkata, India. J Med Microbiol. 2014;63: 1696–1703. doi: 10.1099/jmm.0.081307-0 [DOI] [PubMed] [Google Scholar]
  • 60.Viñas MR, Tuduri E, Galar A, Yih K, Pichel M, Stelling J, et al. Laboratory-based prospective surveillance for community outbreaks of Shigella spp. in Argentina. PLoS Negl Trop Dis. 2013;7: e2521. doi: 10.1371/journal.pntd.0002521 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Azmi IJ, Khajanchi BK, Akter F, Hasan TN, Shahnaij M, Akter M, et al. Fluoroquinolone Resistance Mechanisms of Shigella flexneri Isolated in Bangladesh. PLoS One. 2014;9: e102533. doi: 10.1371/journal.pone.0102533 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Ezernitchi AV, Sirotkin E, Danino D, Agmon V, Valinsky L, Rokney A. Azithromycin non-susceptible Shigella circulating in Israel, 2014–2016. PLOS ONE. 2019;14: e0221458. doi: 10.1371/journal.pone.0221458 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Nandy S, Dutta S, Ghosh S, Ganai A, Rajahamsan J, Theodore RBJ, et al. Foodborne-associated Shigella sonnei, India, 2009 and 2010. Emerg Infect Dis. 2011;17: 2072–2074. doi: 10.3201/eid1711.110403 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Cheng T, Shi X, Yong W, Wang J, Xie G, Ding J. Molecular typing of Shigella sonnei isolates circulating in Nanjing, China, 2007–2011. J Infect Dev Ctries. 2014;8: 1525–1532. doi: 10.3855/jidc.4933 [DOI] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0011964.r001

Decision Letter 0

Stuart D Blacksell, Sivanantham Krishnamoorthi

27 Dec 2023

Dear Author,

Thank you very much for submitting your manuscript "Prevalence and changing antimicrobial resistance profiles of Shigella spp. isolated from diarrheal patients in Kolkata during 2011-2019" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Dear Author,

The manuscript requires minor modification as suggested below.

Reviewer 1:- No changes suggested

The study is well planned and all methods followed are standard. This is a retrospective analysis, they have achieved all the objectives. The results are in line with the analysis plan with all the results well depicted and clearly stated. The conclusions are supported by the data presented. The authors have addressed public helath as well as importance of antibioc resistance surveillance emphasizing development of treatment guidelines. This is a retrospective analysis which is well planned. The study highlights the importance of evolving antibiotic resistance with clonal diversity.

Reviewer 2:- Minor Revision

The authors retrospectively analysed the occurrence, characteristics, and antimicrobial resistance patterns of various Shigella serotypes isolated from patients with acute diarrhea of the Infectious Diseases Hospital in Kolkata from 2011–2019.

The following are the minor comments to be included by the authors:

Study design, statistical analysis method and ethical approval to be mentioned.

The conclusion and limitation of the study, if any to be mentioned.

1. Line 110: Mention the references of studies that have been made across the world to track the epidemiology and antimicrobial susceptibility patterns of Shigella spp.

2. Mention the stool macroscropy characteristics (bloody diarrhoea/ watery diarrhoea)

3. Whether all Shigella spp. were typable or few non-typable strains were there.

4. Please mention why during AMR gene detection for β-lactamase genes blaOXA and blaTEM was choosed and not CTX-M?

5. Mention in discussion regarding the gryB and parC prevalence in comparison to your findings both in India and globally

6. Grammatical corrections needed in the introduction and discussion part.

7. Conclusion and limitation of the study, if any to be mentioned.

8. Study design, statistical analysis method and ethical approval to be mentioned.

9. Ethical approval to be mentioned.

Reviewer 3:- A few minor edits are needed, as indicated in the reviewed file.

The study has been carried out systematically and study design and analysis have been done appropriately. The results have been delineated very systemically and presented appropriately. The study highlights the importance emerging resistance and emphasizes the evolving resistance pattern over a nine-year period from 2011 to 2019. The authors have carried out the study systematically, clearly delineated the findings from the testing and emphasize the emerging resistance patterns.

Regards,

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Sivanantham Krishnamoorthi

Guest Editor

PLOS Neglected Tropical Diseases

Stuart Blacksell

Section Editor

PLOS Neglected Tropical Diseases

***********************

Dear Author,

The manuscript requires minor modification as suggested below.

Reviewer 1:- No changes suggested

The study is well planned and all methods followed are standard. This is a retrospective analysis, they have achieved all the objectives. The results are in line with the analysis plan with all the results well depicted and clearly stated. The conclusions are supported by the data presented. The authors have addressed public helath as well as importance of antibioc resistance surveillance emphasizing development of treatment guidelines. This is a retrospective analysis which is well planned. The study highlights the importance of evolving antibiotic resistance with clonal diversity.

Reviewer 2:- Minor Revision

The authors retrospectively analysed the occurrence, characteristics, and antimicrobial resistance patterns of various Shigella serotypes isolated from patients with acute diarrhea of the Infectious Diseases Hospital in Kolkata from 2011–2019.

The following are the minor comments to be included by the authors:

Study design, statistical analysis method and ethical approval to be mentioned.

The conclusion and limitation of the study, if any to be mentioned.

1. Line 110: Mention the references of studies that have been made across the world to track the epidemiology and antimicrobial susceptibility patterns of Shigella spp.

2. Mention the stool macroscropy characteristics (bloody diarrhoea/ watery diarrhoea)

3. Whether all Shigella spp. were typable or few non-typable strains were there.

4. Please mention why during AMR gene detection for β-lactamase genes blaOXA and blaTEM was choosed and not CTX-M?

5. Mention in discussion regarding the gryB and parC prevalence in comparison to your findings both in India and globally

6. Grammatical corrections needed in the introduction and discussion part.

7. Conclusion and limitation of the study, if any to be mentioned.

8. Study design, statistical analysis method and ethical approval to be mentioned.

9. Ethical approval to be mentioned.

Reviewer 3:- A few minor edits are needed, as indicated in the reviewed file.

The study has been carried out systematically and study design and analysis have been done appropriately. The results have been delineated very systemically and presented appropriately. The study highlights the importance emerging resistance and emphasizes the evolving resistance pattern over a nine-year period from 2011 to 2019. The authors have carried out the study systematically, clearly delineated the findings from the testing and emphasize the emerging resistance patterns.

Regards,

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: The study is well planned and all methods followed are standard. This is a retrospective analysis, they have achieved all the objectives.

Reviewer #2: Study design, statistical analysis method and ethical approval to be mentioned

Reviewer #3: The study has been carried out systematically and study design and analysis have been done appropriately

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: The results are in line with the analysis plan with all the results well depicted and clearly stated.

Reviewer #2: Yes

Reviewer #3: The results have been delineated very systemically and presented appropriately.

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The conclusions are supported by the data presented. The authors have addressed public helath as well as importance of antibioc resistance surveillance emphasizing development of treatment guidelines.

Reviewer #2: Conclusion and limitation of the study, if any to be mentioned

Reviewer #3: The study highlights the importance emerging resistance and emphasizes the evolving resistance pattern over a nine-year period from 2011 to 2019

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: No changes suggested

Reviewer #2: Minor Revision

Reviewer #3: Table 1 can be reduced in size to fit in

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: This is a retrospective analysis which is well planned. The study highlights the importance of evolving antibiotic resistance with clonal diversity.

Reviewer #2: The authors retrospectively analysed the occurrence, characteristics, and antimicrobial resistance patterns of various Shigella serotypes isolated from patients with acute diarrhea of the Infectious Diseases Hospital in Kolkata from 2011–2019.

The following are the minor comments to be included by the authors:

1. Line 110: Mention the references of studies that have been made across the world to track the epidemiology and antimicrobial susceptibility patterns of Shigella spp.

2. Mention the stool macroscropy characteristics (bloody diarrhoea/ watery diarrhoea)

3. Whether all Shigella spp. were typable or few non-typable strains were there.

4. Please mention why during AMR gene detection for β-lactamase genes blaOXA and blaTEM was choosed and not CTX-M?

5. Mention in discussion regarding the gryB and Par C prevalence in comparison to your findings both in India and globally

6. Grammatical corrections needed in the introduction and discussion part.

7. Conclusion and limitation of the study, if any to be mentioned.

8. Study design, statistical analysis method and ethical approval to be mentioned.

Reviewer #3: The authors have carried out the study systematically, clearly delineated the findings from the testing and emphasize the emerging resistance patterns

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Dr Kamran Zaman

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article's retracted status in the References list and also include a citation and full reference for the retraction notice.

Attachment

Submitted filename: PNTD-D-23-01227_r.pdf

pntd.0011964.s008.pdf (4.1MB, pdf)
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0011964.r003

Decision Letter 1

Stuart D Blacksell, Sivanantham Krishnamoorthi

2 Feb 2024

Dear Dr. Mukhopadhyay,

We are pleased to inform you that your manuscript 'Prevalence and changing antimicrobial resistance profiles of Shigella spp. isolated from diarrheal patients in Kolkata during 2011-2019' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Sivanantham Krishnamoorthi

Guest Editor

PLOS Neglected Tropical Diseases

Stuart Blacksell

Section Editor

PLOS Neglected Tropical Diseases

***********************************************************

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0011964.r004

Acceptance letter

Stuart D Blacksell, Sivanantham Krishnamoorthi

14 Feb 2024

Dear Dr. Mukhopadhyay,

We are delighted to inform you that your manuscript, "Prevalence and changing antimicrobial resistance profiles of Shigella spp. isolated from diarrheal patients in Kolkata during 2011-2019," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Primer list for virulence gene.

    (DOCX)

    pntd.0011964.s001.docx (22.4KB, docx)
    S2 Table. Primer list for antimicrobial resistance gene.

    (DOCX)

    pntd.0011964.s002.docx (35.3KB, docx)
    S1 Fig. Trends for S. sonnei isolation rate with relation to seasonality.

    (TIF)

    pntd.0011964.s003.tif (365.4KB, tif)
    S2 Fig. The trends for S.flexneri isolation rate with relation to seasonality.

    (TIF)

    pntd.0011964.s004.tif (361KB, tif)
    S3 Fig. Similarity among the Shigella boydiiisolateson the basis of their plasmid profiles.

    (TIF)

    pntd.0011964.s005.tif (96.4KB, tif)
    S4 Fig. Similarity among the Shigella flexneri 2a isolates on the basis of their plasmid profiles.

    (TIF)

    pntd.0011964.s006.tif (589.4KB, tif)
    S5 Fig. Similarity among the Shigella sonnei isolates on the basis of their plasmid profiles.

    (TIF)

    pntd.0011964.s007.tif (424.5KB, tif)
    Attachment

    Submitted filename: PNTD-D-23-01227_r.pdf

    pntd.0011964.s008.pdf (4.1MB, pdf)
    Attachment

    Submitted filename: PLOsNTD resubmission cover letter.docx

    pntd.0011964.s009.docx (21.4KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files. The sequences submitted in the GenBank are available with accession number PP196524 to PP196533.


    Articles from PLOS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES